# CI-RAG Analysis Report

**Program:** EGFR Degrader
**Query:** Update: Final validation test
**Date:** 2025-11-10

---


## Executive Summary

- **Safety risk**: AE data for NCT12345678, AE reveals safety liability in drug class. Stance: Neutral. [S1]
- **Neutral**: ORR data for NCT12345678, ORR noted. Stance: Neutral. [S2]
- **Neutral**: PFS data for NCT12345678, PFS noted. Stance: Neutral. [S3]
- **Neutral**: DCR data for NCT12345678, DCR noted. Stance: Neutral. [S4]

## What Happened

- NCT12345678, ORR: ORR data (value=45, unit=%) [S1]
- NCT12345678, PFS: PFS data (value=6.2, unit=months) [S2]
- NCT12345678, DCR: DCR data (value=85, unit=%) [S3]
- NCT12345678, AE: AE data (value=58, unit=%) [S4]

## Why It Matters to EGFR Degrader

### Neutral Developments

- Neutral: ORR data for NCT12345678, ORR noted.

- Neutral: PFS data for NCT12345678, PFS noted.

- Neutral: DCR data for NCT12345678, DCR noted.


## Recommended Actions

1. **Enhance safety monitoring protocol** - Owner: Medical - Horizon: 1 week - Confidence: 95%
2. **Monitor competitive landscape** - Owner: CI Team - Horizon: Ongoing - Confidence: 60%
3. **Monitor competitive landscape** - Owner: CI Team - Horizon: Ongoing - Confidence: 60%

## Evidence Table

| ID | Claim | Key Numbers | Date | Source |
|----|-------|-------------|------|--------|
| F1 | ORR data | value=45, n=150 | 2024-12-15 | doc_sample_001 |
| F2 | PFS data | value=6.2, n=150 | 2024-12-15 | doc_sample_001 |
| F3 | DCR data | value=85, n=150 | 2024-12-15 | doc_sample_001 |
| F4 | AE data | value=58, n=150 | 2024-12-15 | doc_sample_001 |

*All numbers are traceable to verbatim quotes in source documents.*


## Confidence and Risks

- **Data Confidence**: 80% based on 4 factual data points
- **Signal Quality**: 1/4 signals have high relevance (score â‰¥0.7)
- **Limitations**: Analysis based on available sources; may not reflect unreported developments

## Sources

1. **doc_sample_001** (2024-12-15)
   > "Objective Response Rate (ORR): 45% (95% CI: 38-52%)"